In response to She et al., “Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater”
Keyword(s):
2020 ◽
pp. ejhpharm-2020-002208
Keyword(s):
Keyword(s):
Keyword(s):